Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NoLEEta adjuvant ribociclib chemotherapy de-escalation trial in intermediate-risk HR-positive HER2-negative early breast cancer
2025-520979-13-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Invasive breast cancer-free survival. Planned start Dec 2025; status: authorised.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-520979-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520979-13-00.